Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Clinical Chemistry|March 3, 1999
Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?W SteimerThe Pharmacogenomics Journal|May 20, 2009
Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?B Laika, S Leucht, S Heres, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|June 20, 2001
Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapyW Steimer, B Müller, S Leucht, et al.Lancet (London, England)|October 8, 1999
Intoxication due to negative canrenone interference in digoxin drug monitoringW Steimer, C Müller, B Eber, et al.The Pharmacogenomics Journal|March 12, 2008
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gainJ Popp, S Leucht, S Heres, et al.Morphologia Medica|September 1, 1983
[Influence of anatomical variations of the pancreatic artery on the surgical technic of segmental pancreas transplantation in dogs]E Steiner, P Gruner, H Schneeberger, et al.The Pharmacogenomics Journal|July 29, 2009
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcomeB Laika, S Leucht, S Heres, et al.Psychopharmacology|February 15, 2000
Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatientsS Leucht, H J Hackl, W Steimer, et al.Journal of Clinical Psychopharmacology|July 31, 2001
Doxepin plasma concentrations: is there really a therapeutic range?S Leucht, W Steimer, S Kreuz, et al.Transplantation Proceedings|December 21, 2010
Neither mycophenolate acyl-glucuronide levels nor their areas under the curve are responsible for the gastrointestinal side effects in kidney transplant recipients receiving EC-MPA: a prospective trialM C Raggi, S B Siebert, D K Abendroth, et al.Pageof 2